The price of Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $9.35 in the last session, down -5.65% from day before closing price of $9.91. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 789083 shares were traded.
Ratios:
We take a closer look at VYGR’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.80. For the most recent quarter (mrq), Quick Ratio is recorded 4.96 and its Current Ratio is at 4.96. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on March 26, 2024, initiated with a Buy rating and assigned the stock a target price of $22.
On March 19, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On March 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $16.Citigroup initiated its Buy rating on March 07, 2024, with a $16 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Sandrock Alfred sold 12,115 shares for $9.86 per share. The transaction valued at 119,454 led to the insider holds 322,839 shares of the business.
Swartz Robin sold 1,357 shares of VYGR for $13,407 on Apr 02 ’24. The Chief Operating Officer now owns 117,004 shares after completing the transaction at $9.88 per share. On Feb 21 ’24, another insider, Sandrock Alfred, who serves as the President and CEO of the company, sold 13,033 shares for $7.46 each. As a result, the insider received 97,226 and left with 334,954 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 538.12M and an Enterprise Value of 327.54M. As of this moment, Voyager’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.02. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.03 while its Price-to-Book (P/B) ratio in mrq is 1.74. Its current Enterprise Value per Revenue stands at 1.31 whereas that against EBITDA is 2.59.
Stock Price History:
Over the past 52 weeks, VYGR has reached a high of $14.34, while it has fallen to a 52-week low of $6.06. The 50-Day Moving Average of the stock is 8.55, while the 200-Day Moving Average is calculated to be 8.35.
Shares Statistics:
According to the various share statistics, VYGR traded on average about 830.58K shares per day over the past 3-months and 810.37k shares per day over the past 10 days. A total of 44.04M shares are outstanding, with a floating share count of 42.78M. Insiders hold about 21.22% of the company’s shares, while institutions hold 48.34% stake in the company. Shares short for VYGR as of Mar 15, 2024 were 2.31M with a Short Ratio of 2.78, compared to 2.15M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.26% and a Short% of Float of 5.09%.
Earnings Estimates
The company has 9 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.44 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.52, while EPS last year was $2.94. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.32 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$0.6 and -$2.9 for the fiscal current year, implying an average EPS of -$1.8. EPS for the following year is -$1.73, with 9 analysts recommending between $0.15 and -$4.18.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $9.41M. It ranges from a high estimate of $16M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $150.48M, an estimated decrease of -93.70% from the year-ago figure.
A total of 10 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $90.14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $38.84M. In the same quarter a year ago, actual revenue was $250.01M, down -84.50% from the average estimate.
